NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW), a company developing targeted therapeutic compounds to treat serious disease, today announced it has signed a Letter of Intent (LOI) with YIACO Medical Co. of Kuwait, for the commercialization of DAVANAT® for the treatment of colorectal and biliary cancer. YIACO Medical serves 18 countries and represents 80 healthcare companies in the Middle East and North Africa with a population of more than 400 million.
